Lucid Diagnostics’ Bold Move: A Lifeline for Cancer Prevention or Market Gamble?
Lucid Diagnostics, specializing in cancer prevention, announces a public offering of common stock to fuel growth and innovation. Key innovations include the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell…